SCCAg、TAP、CEA对宫颈癌新辅助化疗疗效的评估价值  

Values of SCCAg,TAP and CEA in evaluating the efficacy of neoadjuvant chemotherapy for cervical cancer

作　　者：汪萍萍[1] 冯六连[1] Wang Pingping;Feng Liulian(Department of Gynaecology,Huangshi Central Hospital of Edong Healthcare Group (Affiliated Hospital of Hubei Polytechnic University),Huangshi 435000,China)

机构地区：[1]鄂东医疗集团黄石市中心医院(湖北理工学院附属医院)妇科,435000

出　　处：《国际肿瘤学杂志》2018年第10期604-609,共6页Journal of International Oncology

摘　　要：目的探讨鳞状细胞癌抗原(SCCAg)、肿瘤异常蛋白(TAP)、癌胚抗原(CEA)对宫颈癌新辅助化疗疗效的评估价值。方法选取2015年9月至2017年9月本院新辅助化疗治疗的宫颈癌患者100例,同期选取健康人员100例作为对照组,检测所有人员血清SCCAg、TAP、CEA水平,分析SCCAg、TAP、CEA水平与化疗疗效的关系。采用受试者工作特征(ROC)曲线分析不同指标评估宫颈癌新辅助化疗疗效的效能。结果宫颈癌患者SCCAg[(4.95±0.65)μg/L∶(0.22±0.04)μg/L]、TAP[(175.21±25.42)μm^2∶(75.45±9.98)μm^2]、CEA[(35.65±4.23)ng/ml∶(1.26±0.34)ng/ml]水平明显高于对照组,差异有统计学意义(t=75.382,P<0.001;t=62.215,P<0.001;t=55.452,P<0.001)。100例宫颈癌患者化疗3个月后,完全缓解(CR)6例(6.00%)、部分缓解(PR)50例(50.00%)、病情稳定(SD)26例(26.00%)、疾病进展(PD)18例(18.00%)。在SCCAg、TAP、CEA水平方面,CR患者[(2.12±0.32)μg/L∶(4.90±0.52)μg/L、(133.12±14.22)μm^2∶(175.12±24.32)μm^2、(10.34±2.42)ng/ml∶(38.21±7.82)ng/ml]和PR患者化疗后较化疗前[(3.22±0.47)μg/L∶(4.94±0.53)μg/L、(145.22±17.77)μm^2∶(179.52±25.53)μm^2、(16.75±3.02)ng/ml∶(39.12±7.92)ng/ml]显著降低,差异有统计学意义(t=11.153,P<0.001;t=3.562,P=0.004;t=8.340,P<0.001;t=17.169,P<0.001;t=7.797,P<0.001;t=18.662,P<0.001);PD患者化疗后较化疗前[(7.21±0.84)μg/L∶(5.06±0.57)μg/L、(213.21±29.64)μm^2∶(171.56±26.87)μm^2、(46.64±5.12)ng/ml∶(35.75±7.88)ng/ml]均明显上升,差异有统计学意义(t=8.986,P<0.001;t=4.417,P<0.001;t=4.917,P<0.001);SD患者化疗前后比较[(5.03±0.57)μg/L∶(4.97±0.55)μg/L、(175.51±23.37)μm^2∶(176.27±26.55)μm^2、(35.26±7.34)ng/ml∶(37.04±7.73)ng/ml],差异无统计学意义(t=0.386,P=0.701;t=0.110,P=0.913;t=0.851,P=0.399)。ROC曲线分析结果显示,SCCAg评估宫颈癌新辅助化疗疗效的敏感性、特异性、准确率分别为85.71%、81.82%、84.00%,TAP分别为82.14%、77.27%、80.00%,CEA分别为78.57%�Objective To investigate the values of squamous cell carcinoma antigen (SCCAg), tumor abnormal protein (TAP), carcinoembryonic antigen (CEA) in evaluating the efficacy of neoadjuvant chemotherapy for cervical cancer.Methods A total of 100 patients with cervical cancer treated by neoadjuvant chemotherapy were selected from September 2015 to September 2017 in our hospital, and 100 healthy persons were selected as the control group at the same time. The serum levels of SCCAg, TAP and CEA were detected and the relationships between the levels of SCCAg, TAP, CEA and the efficacy of neoadjuvant chemotherapy were analyzed.Results The serum levels of SCCAg [(4.95±0.65)μg/L vs. (0.22±0.04) μg/L], TAP [(175.21±25.42) μm^2 vs. (75.45±9.98) μm^2], CEA [(35.65±4.23) ng/ml vs. (1.26±0.34 )ng/ml] in patients with cervical cancer were significantly higher than those of control group, and the differences were statistically significant (t=75.382, P<0.001;t=62.215, P<0.001;t=55.452, P<0.001). Three months after neoadjuvant chemotherapy for 100 cervical cancer patients, complete remission (CR) was achieved in 6 cases (6.00%), partial remission (PR) in 50 cases (50.00%), stable disease (SD) in 26 cases (26.00%), and progression disease (PD) in 18 cases (18.00%). The SCCAg, TAP and CEA levels of patients with CR [(2.12±0.32) μg/L vs. (4.90±0.52) μg/L, (133.12±14.22) μm^2 vs. (175.12±24.32) μm^2, (10.34±2.42) ng/ml vs. (38.21±7.82) ng/ml] and PR after chemotherapy were significantly lower than those before chemotherapy [(3.22±0.47) μg/L vs. (4.94±0.53) μg/L, (145.22±17.77) μm^2 vs. (179.52±25.53) μm^2, (16.75±3.02) ng/ml vs. (39.12±7.92) ng/ml], and the differences were statistically significant (t=11.153, P<0.001;t=3.562, P=0.004;t=8.340, P<0.001;t=17.169, P<0.001;t=7.797, P<0.001;t=18.662, P<0.001). The above indicators of patients with PD after chemotherapy were significantly higher than those before chemotherapy [(7.21±0.84) μg/L vs. (5.06±0.57) μg/L, (213.21±29.64) μm2vs. (171.56±26.87) μm2, (

关 键 词：宫颈肿瘤 癌胚抗原 化学疗法 辅助 鳞状细胞癌抗原 肿瘤异常蛋白 

分 类 号：R737.33[医药卫生—肿瘤]